Disc Medicine, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IRON Nasdaq 2834 www.discmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Disc Medicine, Inc.

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 2nd, 2026 6:00 am
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Jun 1st, 2026 8:07 am
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients - Jun 1st, 2026 6:30 am
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - May 25th, 2026 10:04 pm
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress - May 12th, 2026 7:30 am
Disc Medicine to Participate in Upcoming Investor Conferences - May 11th, 2026 6:30 am
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter - May 6th, 2026 4:14 pm
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update - May 5th, 2026 6:30 am
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge - Apr 21st, 2026 11:13 am
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 21st, 2026 8:00 am
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Mar 26th, 2026 2:30 pm
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals - Mar 10th, 2026 6:18 pm
What 3 recent FDA rejections reveal about shifts inside the agency - Mar 4th, 2026 12:55 am
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight - Mar 3rd, 2026 3:31 pm
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - Mar 1st, 2026 12:30 pm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's Changed - Feb 28th, 2026 8:11 am
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Feb 26th, 2026 6:30 am
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - Feb 25th, 2026 1:39 pm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - Feb 25th, 2026 1:26 pm
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - Feb 25th, 2026 1:19 pm